News
Corporate News
- 2022
- 06/07 Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
- 06/07 Chordia Therapeutics Concludes Basic Agreement on Collaboration with Shionogi Pharma Co., Ltd
- 05/19 Chordia Therapeutics Concludes Basic Agreement on Business Tie up with MEDIPAL HOLDINGS CORPORATION
- 05/19 Chordia Therapeutics Raises Approximately 4 billion JPY in Series C Financing, Achieving a Cumulative Total of Approximately 8.2 billion JPY
- 05/16 Featured as a cover story in Startup City Magazine’s “Top 10 Japanese Startups 2022”
- 04/07 Nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2022
- 2021
- 12/03 Published 4th financial report
- 09/24 Assignment of Statutory Auditor
- 03/03 Published in Scrip
- 02/04 Published in Answernews
- 2019
- 10/25 Chordia Therapeutics announced the appointment of CMO & CSO
- 03/29 Chordia Therapeutics Raises $~27 million in Series B Financing
- 01/10 Published our article in Forbes JAPAN
- 2017
- 11/30 Chordia Therapeutics Raises $~11 million in Series A Financing
- 11/22 Launch of Chordia Therapeutics